

April 29, 2020

To,
**SINGAPORE EXCHANGE SECURITIES
TRADING LIMITED**
11 North Buona Vista Drive,
#06-07 The Metropolis Tower 2,
Singapore – 138589

Dear Sir,

Sub: Glenmark Pharmaceuticals receives ANDA tentative approval for Dapagliflozin and Saxagliptin Tablets, 10 mg/5 mg

With reference to the subject mentioned above, kindly find attached media release which is self explanatory.

Request you to kindly take the same on record.

Thanking you,

Yours faithfully,
For Glenmark Pharmaceuticals Limited

**HARISH VINAYAK
KUBER**

Digitally signed by HARISH VINAYAK KUBER
DN: c=IN, st=Maharashtra,
2.5.4.20=cde2958f3be913821f999f1026d370afdaabf9b8838ca71de2
e75255a7824, postalCode=400049, street=C21, Muker Kundan Garden,
serialNumber=afdac799832ea525179ba4771e88bf76ef0e3cac49116dc
b1271c80d4b1ee4f, o=Personal, cn=HARISH VINAYAK KUBER
Date: 2020.04.29 10:25:19 +05'30'

Harish Kuber
Company Secretary & Compliance Officer

Encl: as above

Press Release

For Immediate Release

Glenmark Pharmaceuticals receives ANDA tentative approval for Dapagliflozin and Saxagliptin Tablets, 10 mg/5 mg

Mumbai, India, April 29, 2020 – Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted tentative approval by the United States Food & Drug Administration (U.S. FDA) for Dapagliflozin and Saxagliptin Tablets, 10 mg/5 mg, the generic version of Qtern®¹ Tablets, 10 mg/5 mg, of AstraZeneca AB.

According to IQVIA™ sales data for the 12 month period ending February 2020, the Qtern® Tablets, 10 mg/5 mg market² achieved annual sales of approximately \$10.4 million*.

Glenmark's current portfolio consists of 162 products authorized for distribution in the U.S. marketplace and 44 ANDA's pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

About Glenmark Pharmaceuticals - Glenmark Pharmaceuticals Ltd. (GPL) is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries. Glenmark's key therapy focus areas globally are respiratory, dermatology and oncology. It is ranked among the top 80 Pharma & Biotech companies of the world in terms of revenue (SCRIP 100 Rankings published in the year 2019). For more information, visit www.glenmarkpharma.com

For further information, please contact:

Madhurima Gupta Jain
Glenmark, Mumbai, India
Tel: +91 22 4018 1606
Email: corpcomm@glenmarkpharma.com

¹All brand names and trademarks are the property of their respective owners.

²Market includes brand and all available therapeutic equivalents

*IQVIA™ National Sales Perspectives: Retail & Non-Retail, February 2020